JAKKS Pacific (NASDAQ: JAKK) Renews Minecraft Costume Licensing Agreement

March 26, 2026

Key Developments JAKKS Pacific (NASDAQ: JAKK), through its global costume division Disguise, Inc., has secured a multi-year extension of its licensing agreement for Minecraft costumes and accessories. This renewal reflects the ongoing successful partnership between Disguise and the iconic gaming brand Minecraft. The agreement reinforces Minecraft’s role as a leading license in Disguise’s product portfolio, emphasizing JAKKS Pacific’s commitment to maintaining its strong presence in the licensed costume market globally….

Read More >>

Celularity (NASDAQ: CELU) Announces Strategic $35 Million License Partnership

March 26, 2026

Market Overview Celularity (NASDAQ: CELU), a company specializing in regenerative and cellular medicine, has taken a significant step forward with a new strategic licensing deal valued at $35 million. This move highlights the growing interest in longevity science and the commercialization potential of placental-derived biomaterials. Following the announcement, CELU stock may attract attention as investors assess the company’s enhanced capital position to support future growth. In recent months, Celularity (NASDAQ:…

Read More >>

Foresight Autonomous Holdings (NASDAQ: FRSX) Reports 2025 Financial Results

March 26, 2026

Key Developments Foresight Autonomous Holdings (NASDAQ: FRSX) released its financial outcomes for the fourth quarter and entire year ending December 31, 2025, highlighting solid progress. The company emphasized the establishment of significant strategic partnerships throughout the year that have bolstered its market positioning. CEO Haim Siboni underscored the momentum gained from key collaborations with global industry leaders such as Renault Group, Orange, SoftBank Corp., and Audi AG. These partnerships validate…

Read More >>

ParaZero Technologies (NASDAQ: PRZO) Partners with XTEND to Enhance Drone Defense

March 26, 2026

Expert Analysis ParaZero Technologies Ltd. (NASDAQ: PRZO) is positioning itself at the forefront of drone interception through its latest strategic move. By teaming up with XTEND, a company specializing in AI-powered autonomous drones, ParaZero is expanding its capabilities in the rapidly evolving unmanned aerial systems (UAS) market. This partnership highlights ParaZero’s commitment to enhancing defense solutions for both manned and unmanned aerial platforms. Given the increasing complexity and threat landscape…

Read More >>

Enlivex Ltd. (NASDAQ: ENLV) Highlights New AI-Powered Prediction Market Interface

March 26, 2026

Market Overview Enlivex Ltd. (NASDAQ: ENLV), a pioneering firm in the longevity sector, continues to attract attention following its innovative approach to leveraging prediction markets. The company is uniquely positioned within the market due to its connection with the Rain protocol, which supports decentralized prediction markets. This development aligns with broader trends of utilizing AI and decentralized platforms to enhance market capabilities. Recently, the Rain Foundation associated with Enlivex Ltd….

Read More >>

Polyrizon Ltd. (NASDAQ: PLRZ) Files Annual Report for Fiscal Year 2025

March 25, 2026

Market Overview Polyrizon Ltd. (NASDAQ: PLRZ), a biotechnology firm focused on intranasal protective therapies, has recently provided an important update amidst the broader biopharmaceutical market activities. As the biotech sector continues to attract attention for innovation and potential growth, investors often look for transparent disclosures to assess company health and future prospects. The stock for Polyrizon Ltd. has shown steady interest from the market due to its pre-clinical stage developments…

Read More >>

Oragenics (NYSE American: OGEN) Reports Audit Opinion with Going Concern Note

March 25, 2026

Market Overview Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotech company focusing on brain-targeted intranasal therapeutics, recently disclosed its audited financials for fiscal year 2025. The report confirmed an unqualified opinion from their independent audit firm, signaling general compliance with accounting standards. Despite this positive outcome, an explanatory note highlighted concerns about the company’s ability to continue as a going concern. This news places Oragenics (NYSE American: OGEN) under close…

Read More >>

Polyrizon Ltd. (NASDAQ: PLRZ) Files Annual Report for Fiscal Year 2025

March 25, 2026

Key Developments Polyrizon Ltd. (NASDAQ: PLRZ), a biotechnology company focused on developing intranasal protective solutions, has submitted its Annual Report on Form 20-F for the fiscal year ended December 31, 2025. The filing was completed with the U.S. Securities and Exchange Commission (SEC) on March 25, 2026. This annual report provides comprehensive insights into the progress and operational status of Polyrizon Ltd. (NASDAQ: PLRZ), reflecting the company’s initiatives and financial…

Read More >>

Oragenics (NYSE American: OGEN) Announces Audit Opinion Highlighting Going Concern

March 25, 2026

Key Developments Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotech focused on brain-targeted therapeutics, has received an unqualified audit opinion from its independent accounting firm. This opinion, included in the company’s Annual Report on Form 10-K for 2025 filed on March 16, 2026, features an explanatory paragraph regarding the company’s status as a going concern. The disclosure is in line with NYSE American LLC regulations, specifically Company Guide Section 610(b),…

Read More >>

Polyrizon Ltd. (NASDAQ: PLRZ) Files 2025 Annual Report with SEC

March 25, 2026

Key Developments Polyrizon Ltd. (NASDAQ: PLRZ), an innovative biotech company specializing in intranasal protective treatments, has officially submitted its Annual Report on Form 20-F for the fiscal year ending December 31, 2025. The filing was made with the U.S. Securities and Exchange Commission, marking a regulatory compliance milestone for the company. This filing encompasses a detailed overview of Polyrizon Ltd.’s progress in the pre-clinical development stages and financial performance throughout…

Read More >>